| Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC (AIO-TRK-0315) |
|
|
|
Abstract |
2017 |
|
Thorakale Onkologie
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS9108 |
|
|
| Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC |
|
|
|
Abstract |
2017 |
|
Thorakale Onkologie
|
|
|
| www.jto.org/article/S1556-0864(16)31676-8/fulltext |
|
|
| Guideline adherence in bone targeted therapy of cancer patients with bone metastases in Germany |
|
|
|
Poster |
2017 |
|
Supportive Therapie
|
|
|
|
|
|
| Cisplatin/5-FU (CF) +/- panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD/BDGO/EORTC phase III trial (POWER) |
|
|
|
Abstract |
2017 |
|
Ösophagus-/Magenkarzinome
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4011 |
|
|
| PREPARE: Eine Phase-III-Studie zum Stellenwert einer pro-aktiven Therapiebegleitung (Coaching) in Bezug auf die Patienteneinschätzung der Lebensqualität bei Sunitinibbehandlung eines fortgeschrittenen oder metastasierten nzks |
|
|
|
Sonstige |
2017 |
|
Nierenzellkarzinom
|
|
|
| www.springermedizin.de/prepare/12467498 |
|
|
| AIO LQ-0110: a randomized phase II trial comparing oral doxycycline versus local administration of erythromycin as preemptive treatment strategies of panitumumab-mediated skin toxicity in patients with metastatic colorectal cancer |
|
|
|
Vollpublikation |
2017 |
|
Lebensqualität und PRO
|
|
|
| europepmc.org/articles/PMC5739620 |
|
|
| Localization of the primary tumor (LPT) and maintenance strategies after first line oxaliplatin (Ox), fluoropyrimidine (FP), and bevacizumab (Bev) in metastatic colorectal cancer (mCRC): Results from the AIO 0207 trial |
|
|
|
Abstract |
2017 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3543 |
|
|
| mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109) |
|
|
|
Abstract |
2017 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
|
|
| academic.oup.com/annonc/article/28/suppl_5/mdx393.002/4109774 |
|
|
| NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5 fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliarytract cancer: An open label, randomized, multicenter phase II trial of the AIO |
|
|
|
Poster |
2017 |
|
Hepatobiliäre Tumoren
|
|
|
| oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/NIFE-Trial-Liposomal-irinotecan-nal-IRI-plus-5-fluorouracil-5-FU-and-leucovorin-LV-or-gemcitabine-plus-cisplatin-in-advanced-biliary-tract-cancer-an-open-label-randomized-multicenter-phase-II-trial-of-the-AIO |
|
|
| Use of Complementary and Alternative Medicine in Cancer Patients: A Prospective Questionnaire-Based Study in an Oncological Outpatient Clinic |
|
|
|
Vollpublikation |
2016 |
|
Young Medical Oncologist
|
|
|
| www.ncbi.nlm.nih.gov/pubmed/27173775 |
|
|
